计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V125545-10mg |
10mg |
现货 ![]() |
| |
| V125545-50mg |
50mg |
现货 ![]() |
| |
| V125545-250mg |
250mg |
期货 ![]() |
| |
| V125545-1g |
1g |
期货 ![]() |
| |
| V125545-5g |
5g |
期货 ![]() |
| |
| V125545-25g |
25g |
期货 ![]() |
|
| 别名 | 沃替西汀 |
|---|---|
| 英文别名 | Lu AA 21004 | AR-270/43507985 | GG-0052 | Lu AA 21004 | Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine; Lu AA 21004; Vortioxetine | VORTIOXETINE [INN] | FS-3517 | 1-[2-(2,4-dimethylphenylsulfanyl)ph |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Vortioxetine |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 5-HT 1A 受体激动剂;5-HT 1B 受体激动剂;5-HT 1D 受体拮抗剂;5-HT 2A 受体拮抗剂;5-HT 3A 受体拮抗剂;5-HT 5A 受体拮抗剂;5-HT 6 受体拮抗剂;5-HT 7 受体拮抗剂;SERT 抑制剂 |
| 产品介绍 |
Vortioxetine (Lu AA 21004) 是5-HT1A、5-HT1B、5-HT3A、5-HT7受体和 5-羟色胺转运体抑制剂,Ki 值分别为 15、33、3.7、19 和 1.6 nM。它作为抗抑郁药,用于治疗重度抑郁症。
|
| 纯度 | ≥98% |
| PubChem SID | 488196483 |
|---|---|
| EC号 | 823-919-6 |
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine |
| INCHI | 1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3 |
| InChi Key | YQNWZWMKLDQSAC-UHFFFAOYSA-N |
| Smiles | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |
| Isomeric SMILES | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |
| 关联CAS | 508233-74-7 |
| PubChem CID | 9966051 |
| MeSH Entry Terms | 1-(2-(2,4-dimethylphenylsulfanyl)phenyl)piperazine;brintellix;Lu AA21004;Lu-AA21004;LuAA21004;vortioxetine;vortioxetine hydrobromide |
| 分子量 | 298.45 |
| 溶解性 | ≥ 14.9 mg/mL in DMSO;≥ 4.31 mg/mL in EtOH with ultrasonic;insoluble in H2O |
|---|---|
| 分子量 | 298.400 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 298.15 Da |
| 单同位素质量Monoisotopic Mass | 298.15 Da |
| 拓扑极表面积Topological Polar Surface Area | 40.600 Ų |
| 重原子数Heavy Atom Count | 21 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 316.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | Warning |
¥247.12
| 1. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.. J Med Chem, 54 (9): (3206-21). [PMID:21486038] |
| 2. Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. (2018) Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages.. Br J Pharmacol, 175 (1): (113-124). [PMID:29057467] |
| 3. Yunong Li, Haixia Zhu, Jingbo Yang, Kehui Ke, Yanmei Zhu, Li Chen, Youyang Qu, Rui Suo, Xiujie Chen, Yulan Zhu. (2019) Discovering Proangiogenic Drugs in Ischemic Stroke Based on the Relationship between Protein Domain and Drug Substructure. ACS Chemical Neuroscience, 10 (1): (507–517). [PMID:30346717] [10.1021/acschemneuro.8b00381] |